Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;154(9):1807-1819.
doi: 10.1016/j.pain.2013.05.047. Epub 2013 Jun 3.

Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus

Miroslav Misha Backonja  1 , Nadine Attal, Ralf Baron, Didier Bouhassira, Mark Drangholt, Peter J Dyck, Robert R Edwards, Roy Freeman, Richard Gracely, Maija H Haanpaa, Per Hansson, Samar M Hatem, Elena K Krumova, Troels S Jensen, Christoph Maier, Gerard Mick, Andrew S Rice, Roman Rolke, Rolf-Detlef Treede, Jordi Serra, Thomas Toelle, Valeri Tugnoli, David Walk, Mark S Walalce, Mark Ware, David Yarnitsky, Dan Ziegler
Affiliations

Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus

Miroslav Misha Backonja et al. Pain. 2013 Sep.

Erratum in

  • Pain. 2014 Jan;155(1):205

Abstract

Quantitative sensory testing (QST) is a psychophysical method used to quantify somatosensory function in response to controlled stimuli in healthy subjects and patients. Although QST shares similarities with the quantitative assessment of hearing or vision, which is extensively used in clinical practice and research, it has not gained a large acceptance among clinicians for many reasons, and in significant part because of the lack of information about standards for performing QST, its potential utility, and interpretation of results. A consensus meeting was convened by the Neuropathic Pain Special Interest Group of the International Association for the Study of Pain (NeuPSIG) to formulate recommendations for conducting QST in clinical practice and research. Research studies have confirmed the utility of QST for the assessment and monitoring of somatosensory deficits, particularly in diabetic and small fiber neuropathies; the assessment of evoked pains (mechanical and thermal allodynia or hyperalgesia); and the diagnosis of sensory neuropathies. Promising applications include the assessment of evoked pains in large-scale clinical trials and the study of conditioned pain modulation. In clinical practice, we recommend the use QST for screening for small and large fiber neuropathies; monitoring of somatosensory deficits; and monitoring of evoked pains, allodynia, and hyperalgesia. QST is not recommended as a stand-alone test for the diagnosis of neuropathic pain. For the conduct of QST in healthy subjects and in patients, we recommend use of predefined standardized stimuli and instructions, validated algorithms of testing, and reference values corrected for anatomical site, age, and gender. Interpretation of results should always take into account the clinical context, and patients with language and cognitive difficulties, anxiety, or litigation should not be considered eligible for QST. When appropriate standards, as discussed here, are applied, QST can provide important and unique information about the functional status of somatosensory system, which would be complementary to already existing clinical methods.

Keywords: Chronic pain; Neuropathic pain; Quantitative sensory testing; Recommendations; Sensory neuropathies.

PubMed Disclaimer

Comment in

References

    1. Aasvang EK, Brandsborg B, Christensen B, Jensen TS, Kehlet H. Neurophysiological characterization of postherniotomy pain. PAIN® 2008;137:173-181.
    1. Agostinho CM, Scherens A, Richter H, Schaub C, Rolke R, Treede RD, Maier C. Habituation and short-term repeatability of thermal testing in healthy human subjects and patients with chronic non-neuropathic pain. Eur J Pain 2009;13:779-785.
    1. Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D., SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003;26:770-776.
    1. Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Giuliani M, Stevens JC, Barbano R, Dyck PJ. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. A randomized controlled trial. JAMA 2000;17:2215-2221.
    1. Arendt-Nielsen L, Yarnitsky D. Experimental and clinical applications of quantitative sensory testing applied to skin, muscles and viscera. J Pain 2009;10:556-572.